Radiofrequency Ablation of Uterine Fibroids: a Review

Lee, Bruce B.; Yu, Amy S.

doi:10.1007/s13669-016-0183-x

Cited by 43 publications

(36 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No major complications occurred in our series, resulting in a complication rate equal or lower to those reported in literature [32]. In this setting, we could speculate that the use of virtual needle guidance could be helpful in reducing complications related to the poor visualization of the RF electrode active tip, especially during ablation of fibroids closer to sensitive structures.…”

Section: Discussionsupporting

confidence: 49%

Ultrasound-guided transvaginal radiofrequency ablation of uterine fibroids assisted by virtual needle tracking system: a preliminary study

Turtulici¹,

Orlandi²,

Dedone

et al. 2018

International Journal of Hyperthermia

View full text Add to dashboard Cite

Purpose: The purpose of this study was to assess the feasibility and outcome of transvaginal ultrasound (US)-guided radiofrequency ablation of uterine fibroids assisted by a real-time virtual needle tracking (VT) system. Methods: Between January 2017 and February 2018, 19 patients (age 45 ± 8 y, range 36-53 y) with 25 symptomatic uterine fibroids underwent transvaginal radiofrequency ablation (RFA) at a single center. Mean number of fibroids for patient was 1.7 (min, max: 1-3). Patients with more than one fibroid were 10 (52.6%). Uterine fibroids (mean volume: 13.6 mL; range: 5.3-41.9 mL) were treated with a dedicated internally cooled 17 G 35 cm RF needle with 1 cm or variable active tip and the moving shot technique. An electromagnetic system was used for showing a virtual needle during the procedure. Contrastenhanced ultrasound evaluation was performed before and immediately at the end of procedure. Feasibility of the procedure, technical success rate, volume percentage reduction at 1, 3 and 6 months, clinical outcome (QOL score) and complications were analyzed. Results: Procedure was feasible in 19/19 patients (100%). Technical success was achieved in 100% of 25 treated fibroids. Mean fibroids volume decreased from 13.6 ml at baseline to 5.9 ml at 6 month (reduction rate 62.7%, range 48.5-76.9; p < .05). No major immediate or late complications occurred. Minor complications occurred in two patients. QOL score significantly improved from 68 ± 36 at baseline to 97 ± 16 at six-months follow-up (p < .05). Conclusion: Transvaginal US-guided RFA assisted by a real-time VT system is a feasible, safe and effective technique for the treatment of uterine fibroids. ARTICLE HISTORY

show abstract

Section: Discussionsupporting

confidence: 49%

Ultrasound-guided transvaginal radiofrequency ablation of uterine fibroids assisted by virtual needle tracking system: a preliminary study

Turtulici¹,

Orlandi²,

Dedone

et al. 2018

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

“…Under light sedation, a small catheter is introduced via the right common femoral artery to reach and embolize the uterine arteries bilaterally . This procedure treats the whole uterus, rather than the fibroids specifically, and has the potential of permanently impairing uterine and ovarian function . Current pregnancy, suspected cancer, and active pelvic infections are absolute contraindications to this procedure.…”

Section: Managementmentioning

confidence: 99%

“…32 This procedure treats the whole uterus, rather than the fibroids specifically, and has the potential of permanently impairing uterine and ovarian function. 33 Current pregnancy, suspected cancer, and active pelvic infections are absolute contraindications to this procedure. Women undergoing UAE reported an approximate 42% fibroid shrinkage at 3 months, shorter menstrual duration and improvement of bulk symptoms.…”

Section: Uterine Artery Embolizationmentioning

confidence: 99%

Epidemiology and management of uterine fibroids

Giuliani

As‐Sanie

Marsh

2020

Intl J Gynecology & Obste

390

286

View full text Add to dashboard Cite

Uterine leiomyomas are one of the most common and yet understudied diseases in women. These tumors, commonly known as fibroids, affect women mainly during their reproductive years and are diagnosed in up to 70% of white women and more than 80% of women of African ancestry during their lifetime. This disease has a profound impact on health care delivery and costs worldwide. Though most women with fibroids are asymptomatic, approximately 30% of them will present with severe symptoms which can include abnormal uterine bleeding, anemia, pelvic pain and pressure, back pain, urinary frequency, constipation, or infertility, and will require intervention. Furthermore, fibroids have been associated with poor obstetrical outcomes. The current options for symptomatic fibroid treatment include expectant, medical, and surgical management, and interventional radiology procedures. This article reviews the recent progress and available management strategies for uterine fibroids and highlights areas where further research is needed to find new therapeutic targets and better personalize treatments.

show abstract

“…RFA has been described in the selective reduction of complicated monochorionic pregnancies. 76,77 Summary RFA is a safe and effective technology that has reshaped the paradigm of medical therapies. The selection bias in the existing literature and in clinical practice continues to limit the comparison of ablation technologies.…”

Section: Radiofrequency Ablation Outside Of Interventional Radiologymentioning

confidence: 99%

Radiofrequency Ablation, Where It Stands in Interventional Radiology Today

Patel

Ritchie

Padula

et al. 2019

Semin intervent Radiol

View full text Add to dashboard Cite

Radiofrequency ablation (RFA) is one of the first developed minimally invasive definitive cancer therapies. The safety and efficacy of RFA is well documented and has led to its incorporation into multiple international societal guidelines. By expanding on the body of knowledge acquired during the clinical use of RFA, alternative ablative technologies have emerged and are successfully competing for locoregional therapy market share. The adaption of newer ablative technologies is leading to a rapid decline in the utilization of RFA by interventional radiologists despite the lack of proven superiority. In their 2010 article, Hong and Georgiades stated “… RFA is likely to remain the mainstay of ablations for small tumors until sufficient experience emerges for the widespread acceptance for alternative ablative modalities.” Within a decade of this publication, has this time arrived?

show abstract

Radiofrequency Ablation of Uterine Fibroids: a Review

Cited by 43 publications

References 46 publications

Ultrasound-guided transvaginal radiofrequency ablation of uterine fibroids assisted by virtual needle tracking system: a preliminary study

Ultrasound-guided transvaginal radiofrequency ablation of uterine fibroids assisted by virtual needle tracking system: a preliminary study

Epidemiology and management of uterine fibroids

Radiofrequency Ablation, Where It Stands in Interventional Radiology Today

Contact Info

Product

Resources

About